Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

Eitemau Tebyg

• Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
  gan: Seiichi Okabe, et al.
  Cyhoeddwyd: (2014-01-01)
• Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
  gan: Okabe, Seiichi, et al.
  Cyhoeddwyd: (2014)
• Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
  gan: Okabe, Seiichi, et al.
  Cyhoeddwyd: (2013)
• Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
  gan: Okabe, Seiichi, et al.
  Cyhoeddwyd: (2014)
• Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
  gan: Okabe, Seiichi, et al.
  Cyhoeddwyd: (2015)